1. Home
  2. LQDA vs NFJ Comparison

LQDA vs NFJ Comparison

Compare LQDA & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • NFJ
  • Stock Information
  • Founded
  • LQDA 2004
  • NFJ 2005
  • Country
  • LQDA United States
  • NFJ United States
  • Employees
  • LQDA N/A
  • NFJ N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • NFJ Finance: Consumer Services
  • Sector
  • LQDA Health Care
  • NFJ Finance
  • Exchange
  • LQDA Nasdaq
  • NFJ Nasdaq
  • Market Cap
  • LQDA 1.2B
  • NFJ 1.2B
  • IPO Year
  • LQDA 2018
  • NFJ N/A
  • Fundamental
  • Price
  • LQDA $12.21
  • NFJ $12.60
  • Analyst Decision
  • LQDA Strong Buy
  • NFJ
  • Analyst Count
  • LQDA 9
  • NFJ 0
  • Target Price
  • LQDA $27.67
  • NFJ N/A
  • AVG Volume (30 Days)
  • LQDA 2.7M
  • NFJ 223.5K
  • Earning Date
  • LQDA 08-06-2025
  • NFJ 01-01-0001
  • Dividend Yield
  • LQDA N/A
  • NFJ 9.01%
  • EPS Growth
  • LQDA N/A
  • NFJ N/A
  • EPS
  • LQDA N/A
  • NFJ N/A
  • Revenue
  • LQDA $14,144,000.00
  • NFJ N/A
  • Revenue This Year
  • LQDA $185.38
  • NFJ N/A
  • Revenue Next Year
  • LQDA $350.95
  • NFJ N/A
  • P/E Ratio
  • LQDA N/A
  • NFJ N/A
  • Revenue Growth
  • LQDA N/A
  • NFJ N/A
  • 52 Week Low
  • LQDA $8.26
  • NFJ $10.45
  • 52 Week High
  • LQDA $19.41
  • NFJ $12.86
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 35.27
  • NFJ 69.82
  • Support Level
  • LQDA $11.85
  • NFJ $12.16
  • Resistance Level
  • LQDA $13.83
  • NFJ $12.18
  • Average True Range (ATR)
  • LQDA 0.68
  • NFJ 0.12
  • MACD
  • LQDA -0.19
  • NFJ 0.04
  • Stochastic Oscillator
  • LQDA 12.23
  • NFJ 95.45

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest

Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.

Share on Social Networks: